ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2014

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.

Valentin Brodszky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.